Cagrilintide and Semaglutide are injectable peptides used together to support weight management and improve blood sugar control in people with obesity or type 2 diabetes.
Overview
Cagrilintide is a long-acting amylin analog that helps regulate appetite and gastric emptying, promoting satiety and reducing food intake. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances insulin secretion, suppresses glucagon, and slows gastric emptying, improving blood glucose levels.
Combined therapy of Cagrilintide and Semaglutide targets multiple pathways involved in metabolic regulation, making it an effective option for managing obesity and type 2 diabetes by controlling hunger and improving glycemic control.
Research
Clinical studies show that the combination of Cagrilintide and Semaglutide produces greater weight loss and better blood sugar management than either drug alone. Trials report significant reductions in body weight, appetite, and HbA1c levels in treated patients.
Ongoing research focuses on long-term safety, optimal dosing, and potential cardiovascular benefits. This combination represents a promising advancement in pharmacological treatments for metabolic disorders.
Reviews
There are no reviews yet.